The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
There is a great opportunity for utilizing traditional medical practices like Ayurveda in Value Based Healthcare
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company has been issued ‘Form 483’ with two observations
Point-of-Care solution to facilitate clinicians in quick and effective decision making
The top 15 Indian pharma players have continued to experience anaemic growth in the US market over the five years ended FY22
New facility is based at Lonza’s Bend, Oregon (US) site, a Center of Excellence for bioavailability enhancement
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
APAC to see a reduction in imported surgical robotics
Subscribe To Our Newsletter & Stay Updated
